← Back to patent-cliff list
Ibogaine HCl (ATAI Life Sciences/DemeRx)
Tier C — Watch / tradeIbogaine HCl (ATAI Life Sciences/DemeRx)
AtaiBeckley Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：NMDAR, Opioid receptors, Excitatory amino acids
Indications (approved)：药物戒断综合征
Regional status
US
-
EU
Phase II
2021-04-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Ibogaine HCl (ATAI Life Sciences/DemeRx)?
Approved indications include: 药物戒断综合征.
When does the Ibogaine HCl (ATAI Life Sciences/DemeRx) patent expire?
No public expiry year is available for Ibogaine HCl (ATAI Life Sciences/DemeRx) yet; this page updates once verified.
How do I get a quote for Ibogaine HCl (ATAI Life Sciences/DemeRx) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06